Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10392386 JAK inhibitors containing a 4-membered heterocyclic amide

Patent 10392386 was granted and assigned to Theravance on August, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Theravance

Current Assignee

Theravance

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

10392386

Date of Patent

August 27, 2019

Patent Application Number

16222647

Date Filed

December 17, 2018

Patent Citations Received

‌

US Patent 12122773 Crystalline hydrate of a JAK inhibitor compound

‌

US Patent 11299492 JAK kinase inhibitor compounds for treatment of respiratory disease

‌

US Patent 11786517 Methods of treatment using a JAK inhibitor compound

‌

US Patent 11878977 JAK inhibitors containing a 4-membered heterocyclic amide

‌

US Patent 10836763 5 to 7 membered heterocyclic amides as JAK inhibitors

‌

US Patent 10844057 Process for preparing JAK inhibitors and intermediates thereof

‌

US Patent 10947229 Dimethyl amino azetidine amides as JAK inhibitors

‌

US Patent 10954237 JAK inhibitors containing a 4-membered heterocyclic amide

...

Patent Primary Examiner

‌

Joseph R Kosack

Patent abstract

The invention provides compounds of formula (I):

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10392386 JAK inhibitors containing a 4-membered heterocyclic amide

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API